Table 5.
Clinical trials of SIRPα targeted agents in solid tumors
| Code | Inhibitor type | Conditions | Monotherapy or Combination | Number of patients recruited | Phases stage | Clinical trial NO |
|---|---|---|---|---|---|---|
| CC-95251 | Human | Advanced solid and hematologic cancers | Monotherapy, or Combination | 230 participants | Phase I | NCT03783403 |
|
BI 765,063 (OSE-172) |
Humanized IgG4 |
Solid tumors | Combination | 18 participants | Phase I | NCT04653142 |
| Solid tumor, adult | Combination | 116 participants | Phase I | NCT03990233 | ||
|
HNSCC melanoma NSCLC |
Combination | 22 participants | Phase I | NCT05068102 | ||
| HNSCC | Combination | 150 participants | Phase I | NCT05249426 | ||
|
Evorpacept (ALX148) |
mutated SIRPα-Fc IgG1 | HNSCC | Combination | 168 participants | Phase II | NCT04675333 |
| HNSCC | Combination | 183 participants | Phase II | NCT04675294 | ||
| HER2 + gastric cancer | Combination | 450 participants | Phase II/III | NCT05002127 | ||
|
Metastatic cancer; solid tumor; advanced cancer; NHL |
Combination | 174 participants | Phase I | NCT03013218 | ||
|
Microsatellite stable metastatic colorectal cancer |
Combination | 80 participants | Phase II | NCT05167409 | ||
| HER2-expressing cancers | Combination | 93 participants | Phase I/II | NCT05027139 | ||
| TTI-621 | SIRPα-Fc IgG1 | R/R solid tumors and mycosis fungoides | Monotherapy,or combination | 174 participants | Phase I | NCT02890368 |
| Hematologic malignancies solid tumor |
Monotherapy, or combination |
250 participants | Phase I | NCT02663518 | ||
| Leiomyosarcoma | Combination | 80 participants | Phase I/II | NCT04996004 | ||
| TTI-622 | SIRPα-Fc IgG4 | Platinum-resistant ovarian cancer | Combination | 50 participants | Phase I/II | NCT05261490 |